04:23 AM EDT, 08/25/2025 (MT Newswires) -- Biogen (BIIB) and partner Eisai said Monday they have launched Leqembi in Austria, with Germany launch scheduled for Sept 1.

The European Commission approved the drug in April as the first therapy that targets an underlying cause of Alzheimer's disease. It is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to AD.